OPEN Research Support
head

Consultant
Peter Grupe
Department of Nuclear Medicine


Projekt styring
Projekt status    Open
 
Data indsamlingsdatoer
Start 01.07.2020  
Slut 01.07.2025  
 



Is follow-up with diagnostic radioiodine whole-body scintigraphy following first radioiodine treatment in patients with high risk differentiated thyroid cancer unnecessary?

Short summary

Aim/Introduction: The role of diagnostic whole-body scintigraphy (DxWBS) as part of the response evaluation after the initial radioiodine (RAI) therapy of patients with high-risk differentiated thyroid cancer (DTC) is increasingly questioned. Few studies have investigated this issue. This retrospective analysis aimed to investigate the value of DxWBS in combination with TSH-stimulated Thyroglobulin (TSH-Tg) in evaluation of initial treatment efficacy. Materials and Methods: Between 2015-2020 we


Rationale

Aim/Introduction: The role of diagnostic whole-body scintigraphy (DxWBS) as part of the response evaluation after the initial radioiodine (RAI) therapy of patients with high-risk differentiated thyroid cancer (DTC) is increasingly questioned. Few studies have investigated this issue. This retrospective analysis aimed to investigate the value of DxWBS in combination with TSH-stimulated Thyroglobulin (TSH-Tg) in evaluation of initial treatment efficacy.


Description of the cohort

This study included 162 Danish patients with high-risk DTC treated at Odense University Hospital from 2015 to 2020. All patients were adults and had sTg measured in connection with a DxWBS performed with 131I. In accordance with the Danish National Guideline for Treatment of Thyroid Cancer (2), high-risk DTC-patients were defined based on tumor size, histology, metastases and radical or non-radical surgery. All patients had been referred to the Department of Nuclear Medicine for 131I therapy after having a total thyroidectomy performed. The patients were identified via the Radiology Information System in which the descriptions of DxWBS and TxWBS were also found. Pathology results, TNM stage, TSH-stimulation,131I therapy, laboratory results, clinical follow-up, age and gender were collected via hospital records.


Data and biological material

Data from the patients journal (EPJ) - including specified blodsamples and descriptions of dedicated scans from the representative period


Collaborating researchers and departments

Department of Oncology

  • Lars Bastholt